Bridged cyclic ketal derivatives

Abstract

Abstract Compounds are described of formula (I), wherein R1 represents a group selected from (a), (b), (c), (d), -CH¿2?C(CH3)=CHCH(CH2OH)CH2Ph, -CH2C(CH2OH)=CHCH(CH3)CH2Ph, -CH2C(=CH2)CH(OH)CH(CH2OH)CH2Ph, -CH2C(=CH2)CH(NHCOCH3)CH(CH3)CH2Ph, -CH2C(CH2NHCOCH3)=CHCH(CH3)CH2Ph and (e) (where the dotted line represents the absence or presence of a single bond, R?5¿ represents a hydrogen atom or a hydroxyl, acyloxy, C¿1-6? alkoxy or C1-4 alkyl group, R?6¿ represents a hydrogen atom and R7 represents a hydrogen atom or a hydroxyl, C¿1-6? alkoxy or acyloxy group or CR?6R7¿ forms a group C=O, R8 represents a hydrogen atom or a C¿1-4? alkyl group, R?9¿ represents a hydrogen atom or a methyl group, m represents 1 or 2 and n represents zero or 1); R?2, R3 and R4¿ may each independently represent a hydrogen atom or a methyl group; and salts thereof. These compounds inhibit the enzyme squalene synthase and/or are intermediates for the preparation of compounds which inhibit the enzyme squalene synthase. Compounds of the invention may be formulated for use in a variety of conditions where a lowering of the level of blood plasma cholesterol in animals would be beneficial and for use in combating fungal infections in animals.

Inventors

• 👤 Philip James Sidebottom
• 👤 Michael George Lester
• 👤 Panayiotis Alexandrou Procopiou
• 👤 Nigel Stephen Watson
• 👤 Barrie Edward Kirk
• 👤 Barry Clive Ross

Bibliographic Details